Advances Of NSAIDS In Ankylosing Spondylitis

Reference

1. Zonchvan der Linden S, van Tubergen A, Hidding A (2002) Physiotherapy in ankylosing spondylitis: what is the evidence? Clin Exp Rheumatol 20[6 Suppl 28]: S60- S66
2. Miceli-Richard C, Dougados M (2002) NSAIDS in ankylosing spondylitis. Clin Exp Rheumatol 20[6 Suppl 28]:S65-S66
3. Dougados M (2001) Treatment of Spondyloarthropathies. Recent advances and prospects in 2001. Joint Bone Spine 68(6):557- 563
4. Braun J, Sieper J (2004) Biological therapies in the spondyloarthritides-the current state. Rheumatology 43(9): 1072-1084
5. Amor B, Dougados M, Mijiyawa M (1990) Criteria of the classification of spondyloarthropathies Rev Rhum Mal Osteoartic 57(2): 85-89
6. Laine L (2003) Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage 25[2 Suppl]:S32-S40
7. Zochling J, Bohl-Buhler MHJ, Baralikos X, Feldtkeller E, Braun J (2005) The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms. Clin Rheumatol Online First, DOI: 10. 1007/s10067-005-0130-0 
8. Sturrock RD, Hart FD (1974) Double-blind cross-over comparison of     indomethacin, flurbiprofen, and placebo in ankylosing spondylitis Ann Rheum Dis 33(2):129-131
9.  Gran JT (1985) An epidemiological survey of the signs and symptoms of ankylosing spondylitis. Clin Rheumatol 4(2): 161-169
10. Gran JT, Husby G, Hordvik M (1985) Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, Northern Norway. Ann Rheum Dis 44(6):359-367
11. Alamanos Y, Papadopoulos NG, Voulgari PV, Karakatsanis A, Siozos C, Drosos AA (2004) Epidemiology of ankylosing spondylitis in Northwest Greece, 1983-2002.Rheumatology 43(5):615-618
12. Braun J, Pincus T (2002) Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 20[6 Suppl 28]:S16–S22
13. Hardo PG, Chalmers DM, Jakeways M, Wright V, Axon AT (1993) Management of NSAIDs-related dyspepsia in the community. Br J Clin Pract 47(5):241–242
14. Singh G (1998) Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105(1B):31S–38S
15. Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY (2004) Time-dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 63(7):759–766
16. Feldtkeller E, Bruckel J, Khan MA (2000) Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol 12:239–247
17. Feldtkeller E (1999) Erkrankungsalter und Diagnoseverzöger- ung bei Spondylarthropathien. Z Rheumatol 58:21–30
18. Feldtkeller E, Lemmel EM (1999) Zur Situation von Spondy- loarthritis-Patienten. Ergebnisse einer Repräsentativbefragung der Deutschen Vereinigung Morbus Bechterew. Novartis Pharma, Nurembergvan der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27 (4):361–368 
19. Gran JT (1985) An epidemiological survey of the signs and symptoms of ankylosing spondylitis. Clin Rheumatol 4(2):161– 169
20. Braun J, Sieper J: Ankylosing spondylitis. Lancet. 2007, 369:1379-90. 10.1016/S0140-6736(07)60635-7 
21. Sieper J, Rudwaleit M, Baraliakos X, et al.: The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009, 68 Suppl 2:ii1-44. 10.1136/ard.2008.104018 
22. Ward MM, Deodhar A, Akl EA, et al.: American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2016, 68:282-98. 10.1002/art.39298 
23. Chopra A: Disease burden of rheumatic diseases in India: COPCORD perspective. Indian J Rheumatol. 2015, 10:70-7. 10.1016/j.injr.2015.04.002
24. Chopra A, Shankar S: Biosimilar DMARD in rheumatology: a general perspective with a focus on India. Indian J Rheumatol. 2012, 7:89-96. 10.1016/j.injr.2012.04.005 
25. Kay J, Smolen JS: Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis. 2013, 72:1589-93. 10.1136/annrheumdis-2012-203198
26. Bandyopadhyay S, Mahajan M, Mehta T, et al.: Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197. Biosimilars. 2014, 1:1-18. 10.2147/BS.S75573
27. Exemptia™ (adalimumab). (2023). Accessed: February 23, 2023: https://exemptia.com/adalimumabindia.html.
28. Chopra A, Lagoo-Joshi V, Kunjeer V: Our experience with anti-TNF therapy - a choice between the devil and the deep sea. APLAR J Rheumatol. 2005, 9:A208. 
29. Clinical effectiveness of adalimumab (Exemptia™) in patients suffering from symptomatic ankylosing spondylitis (AS) under supervised standard rheumatology care. (2023). Accessed: February 23, 2023: https://ctri.nic.in/Clinicaltrials/pdf_generate.php? trialid=19498&EncHid=&modid=&compid=','19498det%
30. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A: A new approach to defining disease status in ankylosing spondylitis.